Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Daniel O Persky, MD, Thomas P. Miller, MD, Joseph M Unger, PhD, Catherine M. Spier, MD, Soham D. Puvvada, MD, B. Dino Stea, MDPhD, Oliver W. Press, MD PhD, Louis Constine, MD, Kevin Barton, MD, Michael LeBlanc, PhD, Sonali Smith, MD, Richard I. Fisher, MD, Jonathan W. Friedberg, MD

Blood (2014) 124 (21): 4414.

https://doi.org/10.1182/blood.V124.21.4414.4414

Published: 2014

Journal Articles

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Kevin R. Kelly, MD, PhD, Daniel O. Persky, MD, Daruka Mahadevan, MD, PhD, Thomas P. Miller, MD, Soham D. Puvvada, MD, Kevin McDonagh, MD, John Hayslip, MD, Steven I. Park, MD, Jia Ruan, MD, PhD, Peter J. Rosen, MD, Swaminathan Padmanabhan Iyer, MD, MB, BS, Alexandra Stefanovic, MD, Bin Zhang, ScD, Xiaofei Zhou, PhD, Claudio Dansky Ullmann, MD, E. Jane Leonard, MSc, Jonathan W. Friedberg, MD

Blood (2013) 122 (21): 3027.

https://doi.org/10.1182/blood.V122.21.3027.3027

Published: 2013

Journal Articles

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Soham D. Puvvada, MD, Daniel O. Persky, MD, Lora Inclan, Jonathan H. Schatz, MD, Ellen M Chase, Jose Guillen, D Roe, Thomas P. Miller, MD

Blood (2013) 122 (21): 4404.

https://doi.org/10.1182/blood.V122.21.4404.4404

Published: 2013

Journal Articles

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Jennifer R. Brown, MD, PhD, Wael A. Harb, MD, Brian T. Hill, MD, PhD, Janice Gabrilove, MD, Jeff P. Sharman, MD, Marshall T. Schreeder, MD, MPH, Paul M. Barr, MD, James M. Foran, MD, Thomas P. Miller, MD, Jan A. Burger, MD, PhD, Kevin R. Kelly, MD, PhD, Daruka Mahadevan, MD, PhD, Shuo Ma, MD, PhD, Evelyn Barnett, Jeffrey Marine, Pilar Nava-Parada, Ada Azaryan, Jay Mei, MD, Thomas J. Kipps, MD, PhD

Blood (2013) 122 (21): 1630.

https://doi.org/10.1182/blood.V122.21.1630.1630

Published: 2013

Journal Articles

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Blood (2013) 122 (21): 872.

https://doi.org/10.1182/blood.V122.21.872.872

Published: 2013

Journal Articles

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

Paul M. Barr, MD, Margaret M. Briehl, PhD, Steven H Bernstein, MD, Jonathan W. Friedberg, MD, Andrea Baran, MS, Derick R. Peterson, PhD, Daniel Oscar Persky, MD, Carla Casulo, MD, Megan M. Herr, BS, Jamie Littleton, BSN, Erin Cebula, MPH, CCRP, Mark Schwartz, PhD, Soham D. Puvvada, MD, Robert T Dorr, PhD, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2013) 122 (21): 89.

https://doi.org/10.1182/blood.V122.21.89.89

Published: 2013

Journal Articles

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

Blood (2012) 120 (21): 3923.

https://doi.org/10.1182/blood.V120.21.3923.3923

Published: 2012

Journal Articles

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Oliver W. Press, MD, PhD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Jonathan Friedberg, MD, Michael LeBlanc, Ph.D., Myron S. Czuczman, MD, Mark S. Kaminski, MD, Rita M. Braziel, MD, David G. Maloney, MD, PhD, Bruce D. Cheson, MD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2011) 118 (21): 98.

https://doi.org/10.1182/blood.V118.21.98.98

Published: 2011

Journal Articles

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BA, Amy Stejskal, MA, Ann Manziello, BS, Carla Morales, Daniel O. Persky, MD, Richard I Fisher, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2011) 118 (21): 2721.

https://doi.org/10.1182/blood.V118.21.2721.2721

Published: 2011

Journal Articles

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

Heather L. Tardif, Song Yao, PhD, Bryan H. Goldman, MS, Catherine M. Spier, MD, Michael L. LeBlanc, PhD, Lisa M. Rimsza, MD, Daniel O. Persky, MD, Thomas P. Miller, MD, Richard I Fisher, MD, Christine B. Ambrosone, PhD, Margaret M. Briehl, PhD

Blood (2010) 116 (21): 321.

https://doi.org/10.1182/blood.V116.21.321.321

Published: 2010

Journal Articles

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

Jonathan W. Friedberg, MD, Joseph M Unger, Ph.D., W. Richard Burack, Ajay K Gopal, MD, Michael LeBlanc, Ph.D., Oliver W. Press, MD, PhD, Thomas P. Miller, MD, Richard I Fisher, MD

Blood (2010) 116 (21): 590.

https://doi.org/10.1182/blood.V116.21.590.590

Published: 2010

Journal Articles

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Alison T. Stopeck, MD, Joseph M Unger, Ph.D., Lisa M. Rimsza, MD, Brent Farnsworth, DO, Michael LeBlanc, Ph.D., Maria Iannone, MS, Richard I Fisher, MD, Thomas P. Miller, MD

Blood (2010) 116 (21): 591.

https://doi.org/10.1182/blood.V116.21.591.591

Published: 2010

Journal Articles

Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)

Christopher R Flowers, MD, MS, Michael Taylor, PharmD, PhD, Michelle Byrtek, PhD, Jamie H. Hirata, PharmD, James Cerhan, MD, PhD, John Hainsworth, MD, Brian Link, Thomas P. Miller, MD, Hildy Dillon, MPH, Jonathan W. Friedberg, MD

Blood (2010) 116 (21): 1768.

https://doi.org/10.1182/blood.V116.21.1768.1768

Published: 2010

Journal Articles

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Thomas P. Miller, MD, Matthew S Squires, PhD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3930.

https://doi.org/10.1182/blood.V116.21.3930.3930

Published: 2010

Journal Articles

Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma

Daruka Mahadevan, MD, PhD, Laurence Cooke, BS, Xiaobing Liu, BS, Daniel Oscar Persky, MD, Catherine M. Spier, MD, Thomas P. Miller, MD, Wenqing Qi, PhD

Blood (2010) 116 (21): 3933.

https://doi.org/10.1182/blood.V116.21.3933.3933

Published: 2010

Journal Articles

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

Daniel O. Persky, MD, David Dornan, Ph.D, Bryan H Goldman, MS, Rita M. Braziel, MD, Richard I Fisher, MD, Michael LeBlanc, PhD, David G. Maloney, MD, PhD, Thomas P. Miller, MD, Oliver W. Press, MD, PhD, Lisa M. Rimsza, MD

Blood (2009) 114 (22): 111.

https://doi.org/10.1182/blood.V114.22.111.111

Published: 2009

Journal Articles

Targeting Aurora Kinase in Aggressive B-Cell Non-Hodgkin's Lymphomas.

Daruka Mahadevan, MD, PhD, Wenqing Qi, Laurence Cooke, Xiabing Lui, Daniel Oscar Persky, MD, Lisa M. Rimsza, MD, Thomas P. Miller, MD

Blood (2009) 114 (22): 284.

https://doi.org/10.1182/blood.V114.22.284.284

Published: 2009

Journal Articles

Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.

Lisa M. Rimsza, MD, George Wright, Ph.D., Mark Schwartz, PhD, Wing C. Chan, Elaine S Jaffe, MD, Randy D. Gascoyne, MD, Elias Campo, MD, PhD, Andreas Rosenwald, MD, German Ott, MD, James R. Cook, MD, PhD, Raymond R. Tubbs, DO, Rita M. Braziel, MD, Jan Delabie, MD, Thomas P. Miller, MD, Richard I Fisher, MD, Louis M. Staudt, MD, PhD

Blood (2009) 114 (22): 620.

https://doi.org/10.1182/blood.V114.22.620.620

Published: 2009

Journal Articles

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

Thomas P. Miller, MD, Joseph M Unger, MS, Catherine Spier, MD, Baldassarre Stea, MD, PhD, Oliver W. Press, MD, PhD, Jonathan W. Friedberg, MD, Michael LeBlanc, PhD, Richard I Fisher, MD

Blood (2008) 112 (11): 3598.

https://doi.org/10.1182/blood.V112.11.3598.3598

Published: 2008

Journal Articles

Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.

Jonathan W. Friedberg, MD, Anas Younes, M.D., David C. Fisher, MD, Leo I. Gordon, MD, Joseph O. Moore, MD, Myron S. Czuczman, MD, Thomas P. Miller, MD, Patrick J. Stiff, MD, Bruce D. Cheson, MD, Andres Forero-Torres, MD, Byron McKinney, M.D., John P. Leonard, MD

Blood (2008) 112 (11): 1004.

https://doi.org/10.1182/blood.V112.11.1004.1004

Published: 2008

NARROW

Long Term Follow up of SWOG S0313: Ibritumomab Tiuxetan Consolidation after 3 Cycles of CHOP Plus Radiotherapy for High Risk Limited Stage Aggressive B-Cell Lymphoma

Phase 1 Study Of Investigational Agent MLN8237 (Alisertib) + Rituximab ± Vincristine In Patients (Pts) With Relapsed/Refractory (Rel/Ref) Aggressive B-Cell Lymphomas

Yttrium-90-Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy After Cytoreduction With ESHAP Chemotherapy In Patients With Relapsed Follicular Non-Hodgkin’s Lymphoma (NHL): Interim Results Of a Phase II Study

Phase 1 Study Of Single Agent CC-292, a Highly Selective Bruton's Tyrosine Kinase (BTK) Inhibitor, In Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Bcl-2 Inhibitor ABT-199 (GDC-0199) Monotherapy Shows Anti-Tumor Activity Including Complete Remissions In High-Risk Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) and Small Lymphocytic Lymphoma (SLL)

Redox Associated Gene Expression Predicts For Responses To The Pro-Oxidant Molecule Imexon In Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma: Results Of a Multi-Center Phase II Study

The BCL-2-Specific BH3-Mimetic ABT-199 (GDC-0199) Is Active and Well-Tolerated in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Interim Results of a Phase I First-in-Human Study

A Phase III Randomized Intergroup Trial (SWOG S0016) of CHOP Chemotherapy Plus Rituximab Vs. CHOP Chemotherapy Plus Iodine-131-Tositumomab for the Treatment of Newly Diagnosed Follicular Non-Hodgkin's Lymphoma

Mitotic Spindle Assembly Inhibition Through Aurora A (MLN8237) Plus Vincristine Is Synthetic Lethal and Synergizes with Rituximab As a Curative Therapy in Aggressive B-Cell Non-Hodgkin Lymphoma

Genetic Polymorphisms In Oxidative Stress-Related Genes Correlated with Outcome Following Anthracycline-Based Therapy for Aggressive B-Cell Non-Hodgkin Lymphomas

R-CHOP with Iodine-131 Tositumomab Consolidation for Advanced Stage Diffuse Large B-Cell Lymphoma (DLBCL): Southwest Oncology Group Protocol S0433

Phase II Trial of Standard Dose Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (CHOP) and Rituximab (R-CHOP) Plus Bevacizumab for Advanced Stage Diffuse Large B-Cell (DLBCL) NHL: Southwest Oncology Group Study S0515

Does An Anthracycline Make a Difference for Follicular Lymphoma (FL) Grade 3? Patterns of Care and Treatment Outcomes of Grade 3 FL From the National LymphoCare Study (NLCS)

AT9283, a Novel Pan-Aurora/JAK-2 Kinase Inhibitor Suppresses Tumor Growth In Aggressive B-Cell Non-Hodgkin's Lymphoma

Addition of Rituximab to MLN8237 An Aurora A Kinase Inhibitor Plus Vincristine or Docetaxel Has Synergistic Anti-Tumor Activity In a Mouse Model of Aggressive B-Cell Non-Hodgkin's Lymphoma

Fc Gamma Receptor 3a Genotype Predicts Overall Survival for Follicular Lymphoma Patients Treated On Southwest Oncology Group Trials with Combined Monoclonal Antibody Plus Chemotherapy but Not Chemotherapy Alone.

Targeting Aurora Kinase in Aggressive B-Cell Non-Hodgkin's Lymphomas.

Accurate Classification of Diffuse Large B Cell Lymphoma Into Germinal Center and Activated B Cell Subtypes Using a Nuclease Protection Assay On Formalin Fixed Paraffin Embedded Tissue: A Study From the Lymphoma and Leukemia Molecular Profiling Project.

Effect of Adding Ibritumomab Tiuxetan (Zevalin) Radioimmunotherapy Consolidation to Three Cycles of CHOP Plus Involved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG 0313)

Durable Responses in Patients Treated with Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory Follicular Lymphoma: Long-Term Follow-up of a Phase II Clinical Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only